Heart attack death rates rose by 1.2% among adults younger than age 55 who were hospitalized between 2011 and 2022 with a first severe heart attack, according to a February study published in the ...

Credit: Getty Images. A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. The role of beta-blockers after acute ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...

Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...

The authors collected resource utilization and cost of treatment data (in US dollars, excluding physicians' fees) from the cost accounting systems of two Canadian hospitals (n=215) and seven US ...

More than a third of patients were menopausal, and one in seven were men. Experts say awareness is key, but so too are protocols.

Presenter: Stuart J. Connolly, MD, McMaster University (Hamilton, Ontario, CANADA) and Stefan H. Hohnloser, MD, J.W. Goethe University (Frankfurt, Germany) Large randomized clinical trials have ...

A bivalent messenger RNA vaccine targeting both the ancestral and omicron BA.4–BA.5 sublineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Pfizer–BioNTech) was introduced in ...

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...